Astrazeneca

This study tests two experimental vaccines, AZD4117 and AZD5315, designed to protect against certain strains of avian influenza (bird flu), specifically H5N1 and H7N9. Around 405 healthy adults will receive either a vaccine or a placebo to see if the vaccines are safe and trigger…

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

This study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…

This early-stage study tests a new drug called AZD0780 in 40 healthy adults with high LDL (bad) cholesterol. Participants receive either the drug or a placebo to see if it safely lowers cholesterol levels. The goal is to gather initial safety and effectiveness data before moving …

This Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …

This study looks at how safe and effective Fasenra (benralizumab) is for children aged 6 to 14 with severe asthma that isn't controlled by other treatments. Researchers will track side effects and measure lung function and asthma control in 40 children over time. The goal is to s…

This phase 3 study tests whether adding baxdrostat to the standard drug dapagliflozin can better slow chronic kidney disease (CKD) progression in adults with CKD and high blood pressure. About 2,500 participants will receive either the combination or dapagliflozin alone for 24 mo…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This study tracks 416 people with severe asthma that isn't controlled by standard treatments. All participants receive Tezspire injections and are monitored for side effects, including serious allergic reactions, infections, and heart problems. The goal is to see how safe and eff…

This study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it f…

This study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…

This Phase III trial tests whether adding oleclumab or monalizumab to the standard drug durvalumab can help people with stage III non-small cell lung cancer that hasn't worsened after chemoradiation. About 1,050 participants will receive one of the combinations or a placebo. The …

This study is tracking the long-term safety and effectiveness of the drug Saphnelo (anifrolumab) in over 1,600 people with systemic lupus erythematosus who haven't responded well to current treatments. Researchers are monitoring for side effects like serious infections, shingles,…

This study tests whether adding olaparib to standard abiraterone therapy can slow the growth of metastatic castration-resistant prostate cancer better than abiraterone alone. About 110 men who have not had chemotherapy or newer hormone drugs for this stage of cancer will particip…

This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and…

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This study tests whether the drug tezepelumab can help people with severe asthma reduce their daily maintenance inhaler dose without losing control of their asthma. About 326 adolescents and adults will receive tezepelumab injections and then try to step down their usual inhaler …

This Phase 3 trial tests whether a new drug, datopotamab deruxtecan (Dato-DXd), given alone or with another drug (durvalumab), can help prevent breast cancer from returning in people with triple-negative breast cancer who still have cancer cells after initial treatment and surger…

This Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…

This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…

This study follows 254 adults with extensive-stage small cell lung cancer who are receiving durvalumab (Imfinzi) along with standard chemotherapy. The goal is to see how long patients stay on treatment and how well it works in real-world settings. The approach uses the immune sys…

This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…

This study tested a new oral drug, AZD9833, against a standard injected treatment (fulvestrant) in 240 women with advanced ER-positive, HER2-negative breast cancer. The main goal was to see how long the cancer stayed under control. Results from one dose group were limited because…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This study follows 155 adults with severe asthma who are starting tezepelumab, a new biologic drug. Researchers will track symptom control, quality of life, and lung function over two years in real-life clinics across Greece. The goal is to see how well the drug works outside of …

This study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…

This study follows 64 Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking ravulizumab as part of their routine care. Researchers will track blood markers like LDH and how many patients need blood transfusions over time. The goal is to see if the drug works…

This study tests whether taking osimertinib for 5 years after surgery can prevent lung cancer from coming back in people with a specific EGFR mutation. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug. The main go…

This study compares a drug called durvalumab (an immunotherapy that helps the immune system fight cancer) to standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stag…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study tests a new drug called volrustomig combined with chemotherapy against standard treatments for people with advanced pleural mesothelioma that cannot be removed by surgery. About 861 adults with this rare lung cancer will be randomly assigned to receive either the exper…

This phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …

This Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involv…

This study tests a granule (sprinkle) form of the drug selumetinib in children aged 1 to under 7 years who have neurofibromatosis type 1 (NF1) with painful, inoperable tumors. The goal is to find the right dose, check safety, and see if it shrinks tumors. About 36 children will t…

This study tests a drug called eplontersen in Chinese adults with a heart condition caused by abnormal protein buildup. The goal is to see if the drug lowers that protein and is safe over time. Participants will be randomly assigned to receive the drug or a placebo for 24 weeks, …

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This phase 3 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted therapy (enfortumab vedotin) works better than current standard care for people with muscle-invasive bladder cancer who cannot take or refuse cisplatin chemotherapy. A…

This study tests whether adding a new drug called AZD0780 to the common statin rosuvastatin can lower 'bad' LDL cholesterol more than rosuvastatin alone. About 76 adults with high cholesterol will take either AZD0780 or a placebo pill, plus rosuvastatin, for 12 weeks. Neither par…

This phase 3 trial tests whether adding olaparib to standard abiraterone therapy helps men with metastatic castration-resistant prostate cancer live longer without their cancer worsening. About 895 men who have not had chemotherapy or newer hormone drugs for this stage will recei…

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…

This Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …

This study tests an experimental drug called AZD7798 in 24 adults with active Crohn's disease who have an ileostomy. The goal is to see if the drug is safe and can help repair the gut lining compared to a placebo. Participants will be monitored for side effects and changes in the…

This study tests a new drug called AZD7798 in 120 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and improve the appearance of the gut lining. Participants are randomly assigned to receive either the drug or a placebo, and neither the…

This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and …

This phase 3 trial tests whether adding monalizumab to the standard drug cetuximab helps people with recurrent or metastatic head and neck cancer live longer. The study includes 370 adults who have already tried an immune checkpoint inhibitor and platinum-based chemotherapy. Part…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then contin…

This early-stage study tested the safety of an experimental cancer drug called AZD6244, given as a capsule, in 58 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check for side effects and how the drug moves through the b…

This large Phase 3 trial is testing whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy can help people with advanced bladder cancer that cannot be removed by surgery. Over 1,200 participants worldwide are receiving either che…

This study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…

This Phase 3 trial tests whether adding the experimental drug saruparib to standard hormone therapy can slow cancer growth in men with metastatic prostate cancer that still responds to hormone treatment. About 1,889 men will receive either saruparib or a placebo, plus a hormone d…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…

This study tests two versions of the asthma inhaler Symbicort (budesonide/formoterol) in children aged 4 to 12 with asthma. The goal is to see how much of the drug gets into the blood with each version and whether they are safe. Fifteen children will take single doses of both the…

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancer live longer. About 810 participants received either durvalumab or a placebo alongside chemo. The study m…

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…

This phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…

This study tests a new drug called trastuzumab deruxtecan (T-DXd), given alone or with another drug (pertuzumab), against the current standard treatment for HER2-positive breast cancer that has spread. About 1,157 people with this type of cancer will take part. The goal is to see…

This study looks at whether taking selumetinib with a low-fat meal reduces stomach problems in teenagers with neurofibromatosis type 1 (NF1) who have tumors that cannot be removed by surgery. About 24 teens will take the drug under both fed and fasted conditions to compare drug l…

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which com…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…

This study tests whether a structured care program (called a transition bundle) helps people with COPD recover better after a serious flare-up. The program includes guided steps and regular check-ins. About 1,368 patients across 36 hospitals will take part. The goal is to see if …

This study tests an experimental drug called volrustomig in 37 women with high-risk, locally advanced cervical cancer that hasn't gotten worse after standard chemotherapy and radiation. The goal is to see if the drug can help keep the cancer from coming back or spreading. Partici…

This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delay…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemoradiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 640 participants will receive either durvalumab or a placebo alongside their cancer treatment…

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This study follows about 80-100 Chinese children aged 3-16 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. All participants take the drug selumetinib (Koselugo) and are monitored for 24 months to see how well it works and what side ef…

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It included 162 adults whose cancer had previously responded to platinum-based treatm…

This study tests whether the targeted drug osimertinib can help prevent lung cancer from returning after surgery in patients with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take an 80 mg pill daily for up to 3 years. Researche…

This study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The goal is to check the drug's safety and how well it works at shrinking these tumors. Participants take the …

This phase 3 trial tests a new drug called Dato-DXd against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy dr…

This Phase 3 trial tests whether adding zibotentan to the standard drug dapagliflozin can better protect kidney function in people with chronic kidney disease and high proteinuria. About 1,800 adults are taking either the combo or dapagliflozin alone. The main goal is to see if t…

This study follows 125 people aged 12 and older with severe asthma who are starting tezepelumab in Russia. Over 52 weeks, researchers will track how well their symptoms are controlled using a standard questionnaire. The goal is to see how the drug works outside of clinical trials…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…

This Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids.…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it …

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This study tests an experimental oral drug called AZD0780 in 432 adults with high LDL cholesterol (dyslipidaemia). Participants take the drug or a placebo daily for up to 52 weeks to see if it safely lowers cholesterol. The goal is to manage the condition, not cure it, as ongoing…

This early-stage trial tests whether combining the immunotherapy durvalumab with other experimental drugs (danvatirsen, oleclumab) and/or chemotherapy can safely control stage IV non-small cell lung cancer. About 175 people who have not had prior treatment for metastatic disease …

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer. Over 1,100 adults with no prior treatment took part. The goal was to see if the new treatments helped peopl…

This study tests whether a standardized care plan can help chronic kidney disease patients better control high potassium levels while optimizing their RAASi medications. About 1,000 participants will receive the care plan, which includes doctor training and patient education. The…

This Phase 3 trial tests whether a daily pill called AZD0780 can safely lower LDL (bad) cholesterol in adults with heart disease or at high risk. About 3,100 participants will receive either AZD0780 or a placebo for 52 weeks, and neither they nor their doctors will know which the…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …

This Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…

This study tests an experimental drug called AZD0780 in 473 adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The drug aims to lower LDL (bad) cholesterol more than a placebo over 12 weeks, with treatment lasting up to…

This phase 3 study tests whether the targeted drug osimertinib can keep stage III EGFR-mutant lung cancer from progressing after initial chemoradiation. About 216 participants will receive either osimertinib or a placebo daily until their cancer worsens or side effects become una…

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part.…

This Phase II trial tests whether adding olaparib to durvalumab helps keep stage IV non-small cell lung cancer from growing after initial chemotherapy. About 400 patients whose cancer did not worsen on standard chemo plus durvalumab will receive either the combination or durvalum…

This early-stage study tests a new drug called AZD1705 in adults with high cholesterol (dyslipidemia). The main goal is to check if the drug is safe and how the body processes it. About 98 participants will receive either the drug or a placebo. This research helps determine if th…

This early-phase trial tests a new drug called AZD9833, alone or with other medicines, in women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. About 396 women will take part. This is not a c…

This phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy.…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This study tests two different drug combinations in people with advanced EGFR-mutant lung cancer whose disease has worsened after standard targeted therapy. Participants receive either osimertinib plus savolitinib or osimertinib plus selumetinib. The main goal is to check safety …

This phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard radiation therapy helps prevent early-stage non-small cell lung cancer from progressing. It includes about 724 patients who cannot have surgery. A separate group of patients with a specific EGFR…

This Phase 3 study is testing whether a combination of three drugs—datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin—works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that does not h…

This observational study follows 151 Italian adults with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib between May 2021 and April 2022. Researchers want to see how long patients continue the drug and why they might stop, providing real-world insights beyond …

This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimerti…

This phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug…

This study tests an experimental drug called tezepelumab in people aged 12 to 80 with eosinophilic esophagitis, a condition where white blood cells build up in the esophagus, causing trouble swallowing. Participants receive either the drug or a placebo as a shot under the skin. T…

This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can del…

This phase 3 trial tests whether the targeted drug osimertinib (Tagrisso) can prevent lung cancer from returning in patients with early-stage (IA2-IA3) non-small cell lung cancer that has a specific EGFR mutation. About 390 participants who have had complete tumor removal surgery…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…

This study tested adding the immunotherapy drug durvalumab (with or without another drug, tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either chemo alone or ch…

This phase 3 study tests two doses of Nexium (esomeprazole) in 53 children aged 1 to 11 years who have erosive esophagitis, a condition where stomach acid damages the esophagus. The goal is to see which dose better maintains healing after an initial 8-week treatment period. Child…

This early-stage trial is studying whether an experimental drug called AZD6793 changes how the common diabetes medicine metformin works in people with type 2 diabetes. About 28 participants will take both AZD6793 and a placebo alongside their usual metformin to compare effects on…

This study tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than standard chemotherapy for people with advanced bladder cancer that has spread (stage IV). Over 1,100 participants received either the drug combination, durvalumab alone, or chemo. The…

This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the …

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…

This study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see how safe and tolerable the treatment is. About 85 people in…

This study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…

This study tests whether a new drug combination (ceralasertib plus durvalumab) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has stopped responding to prior treatments. About 594 participants will be randomly assigned…

This phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This study tests a drug called tozorakimab in people with chronic obstructive pulmonary disease (COPD) who have a history of flare-ups and high levels of eosinophils (a type of white blood cell). The trial involves 98 participants who receive either tozorakimab or a placebo every…

This study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer t…

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …

This study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This study tests whether switching from a standard rescue inhaler (albuterol alone) to one that also contains an anti-inflammatory steroid (budesonide) can reduce severe asthma attacks. About 1,500 adults with asthma who have had at least one severe attack in the past year will u…

This early-stage trial is testing a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without chemotherapy, in 155 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and shows signs of shrinking tumo…

This large Phase 3 trial tests whether a new combination of drugs (datopotamab deruxtecan plus durvalumab) given before and after surgery works better than the current standard treatment for people with untreated triple-negative or hormone receptor-low/HER2-negative breast cancer…

This phase 3 study tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. About 454 adults who have not had prior tre…

This Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either ben…

This study aimed to test new cancer drugs, alone or in combination, for people with advanced or recurrent ovarian cancer. The treatments were chosen based on specific genetic markers in each person's tumor. However, the study was withdrawn before enrolling any participants, so no…

This phase 3 trial tests a daily pill called osimertinib (AZD9291) against a placebo in 682 people with a specific type of lung cancer (EGFR-mutated, stages IB to IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can delay or prevent the cancer from…

This study tests if a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has spread. The trial is for patien…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This study tests a new drug called rilvegostomig (AZD2936) in people with advanced or metastatic non-small cell lung cancer. The drug is designed to boost the immune system's ability to fight cancer by blocking two targets (TIGIT and PD-1). The trial will check for safety, side e…

This study tests the drug selumetinib in adults with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors called plexiform neurofibromas. About 145 participants will receive either selumetinib or a placebo to see if the drug can shrink the tumors and reduce pa…

This phase II trial tests a drug called trastuzumab deruxtecan (T-DXd) in 102 adults with advanced solid tumors that have specific HER2 mutations. The cancers include types like colorectal, gastric, and ovarian, among others. The goal is to see if the drug can shrink tumors or sl…

This Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …

This study tests an investigational drug called tozorakimab in about 1,454 adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year. Participants continue their usual inhaled medications and receive either tozorakimab or a placebo as…

This Phase 3 trial is testing whether a new drug called volrustomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. The study includes about 1,200 partici…

This study tested whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 1,186 adults with metastatic NSCLC who had not re…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer. About 1,063 participants will receive either the drug combo or standard care. The goal is to see i…

This study follows 192 people with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug for at least 24 months and how it works in different groups, like those new to treatment …

This Phase 2 study tests whether adding another drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial includes 273 adults whose cancer has specific genetic changes. One…

This large global trial is testing whether two experimental drugs—volrustomig (an immunotherapy) and casdatifan (a pill)—work better than the current standard immunotherapy combination for people with advanced clear cell kidney cancer. About 1,100 participants who have not had pr…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …

This phase 3 trial is testing whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy for people with a specific type of advanced breast cancer called HER2-low, hormone receptor positive. The study includes 866 participants whose cancer ha…

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This Phase 2 study tests an experimental drug called AZD6234, given as a weekly injection, for weight loss in adults with overweight or obesity and type 2 diabetes. Participants are already on a stable dose of a GLP-1 medication. The study will compare AZD6234 to a placebo over 2…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…

This phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the…

This phase 3 study tests anifrolumab, an IV drug, against placebo in 359 adults with active lupus nephritis (kidney inflammation from lupus). The main goal is to see if more patients achieve complete kidney response, meaning better kidney function and less protein in urine. The t…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests whether a new propellant (HFO) for the budesonide/albuterol inhaler works as well as the current one (HFA) in adults with asthma. Over 400 participants will use three different inhalers over 12 weeks to compare lung function. The goal is to see if the new propell…

This study is testing the drug dapagliflozin in 731 Chinese adults with chronic kidney disease. The goal is to see if the drug can slow kidney decline and is safe. Participants take the drug by mouth, and researchers track kidney function and side effects over time.

This study is for people with muscle-invasive bladder cancer that has gotten worse after earlier treatments. It tests several different drug combinations, chosen based on the specific genetic markers of each person's tumor. The main goal is to see if these combinations are safe a…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT) before and after surgery helps people with resectable stomach or gastroesophageal junction cancer live longer without the cancer returning. About 957 participants receive either durv…

This phase 3 trial tests whether adding capivasertib (a targeted drug) to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The study is no…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This phase 3 trial tests whether taking olaparib tablets daily can delay the return of advanced ovarian cancer in women with BRCA gene mutations. Participants had already responded to initial platinum chemotherapy. The study compares olaparib to a placebo over up to two years, me…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This phase 3 trial tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help prevent cancer progression in people with limited-stage small cell lung cancer who have completed chemoradiation. About 730 participants will receive either the drug combin…

This phase 3 trial tests whether adding selumetinib (a targeted therapy) to standard chemotherapy (docetaxel) helps people with advanced KRAS-mutant lung cancer live longer without their cancer growing. About 510 adults whose cancer worsened after first treatment will receive eit…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is …

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo …

This study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This study is testing an artificial intelligence (AI) program called qXR that analyzes chest X-rays to give a lung nodule malignancy score — a number that indicates how likely a lung nodule is to be cancer. Researchers will compare the AI's score to the results of CT scans and ra…

This study tests a biologic drug called tezepelumab (Tezspire) in 181 adults with chronic sinusitis and nasal polyps who are eligible for surgery. Participants receive injections every 4 weeks for 24 weeks. The goal is to see if the drug reduces nasal congestion and other sinus s…

This early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This early-stage trial in 48 healthy volunteers checks whether a new drug called elecoglipron changes how the body processes two common statins (atorvastatin and rosuvastatin). Participants take the statin alone and later with elecoglipron, and researchers measure drug levels in …

This early-phase trial is testing the safety and tolerability of a new drug called AZD0292 in 18 healthy Japanese adults. Participants receive a single dose of the drug or a placebo by IV infusion. The study aims to understand how the drug moves through the body and whether it ca…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) in real-life settings in Romania. Researchers will collect data from 250 patients over three years to see how long they stay on the drug, why they stop, and how effective …

This study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…

This study looks at how doctors in Russia treat advanced or metastatic non-small-cell lung cancer in everyday practice. Researchers will follow about 1500 adults across 20 cancer centers to see which treatments and genetic tests are used. The goal is to understand real-world care…

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how b…

This study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizu…

This study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to le…

This study looks at how doctors currently diagnose lung and breast cancer using tissue samples. It will also test whether artificial intelligence (AI) can help analyze these samples faster and more accurately. Researchers will review records from 600 patients to measure diagnosis…

This study looks at over 1,700 people in Russia who have moderate to severe COPD and often have flare-ups. Researchers will collect information on their health, lifestyle, and treatments to better understand the disease. The goal is to learn more about these patients to help impr…

This early-stage study tests a drug called andexanet alfa, which is designed to reverse the effects of common blood thinners like rivaroxaban and apixaban. Researchers will give these blood thinners to 179 healthy volunteers, then give andexanet to see how well it works and how i…

This study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treat…

This study is tracking over 1,200 adults in Kazakhstan who have high blood pressure to see how many also have signs of chronic kidney disease (CKD). Researchers will measure things like protein in urine and kidney function. The goal is to understand how often CKD goes undiagnosed…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why …

This study observes how doctors in Russia treat inoperable lung cancer (NSCLC and SCLC) using chemoradiotherapy. Researchers will collect data from 2000 patients across 50 cancer centers to understand real-world practices and short-term outcomes. No new treatments are given; the …

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…

This early-stage study in 32 healthy adults looks at how a new drug called AZD5004 changes the way the body processes two diabetes medications, mitiglinide and pioglitazone. The goal is to understand potential drug interactions, not to treat any disease. Participants take the dru…

This study looks at 625 people in Russia with high-risk early-stage breast cancer that is HER2-negative. Researchers want to find out how many have BRCA1 or BRCA2 gene mutations and what treatments they receive in real-world practice. Participants provide blood and tumor samples …

This study is creating a registry of 5,000 adults with chronic kidney disease (CKD) to collect information on their health, treatments, and outcomes. Researchers aim to understand how the disease progresses, identify risk factors, and see how well current treatments match guideli…

This study follows 202 Chinese asthma patients who are already prescribed biologic medications. Researchers will track how consistently patients take their biologics over 52 weeks and describe treatment patterns. No new drug is being tested; the goal is to gather real-world data …

This study observes 367 Chinese patients with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. Researchers will track how patients are treated in routine care and monitor their health for up to 12-24 months. The goal is to bet…

This study follows over 800 heart failure patients in Germany who are starting dapagliflozin, a drug recently approved for heart failure. Researchers will track how long patients stay on the drug, any side effects, and changes in symptoms and quality of life. The goal is to under…

This observational study is collecting data from 315 patients in Italy who started treatment with tezepelumab for severe uncontrolled asthma. The goal is to describe their characteristics, medical history, and how their asthma exacerbation rates change over 12 to 24 months. It is…

This study was designed to track how often people in Egypt have severe COPD flare-ups and how those flare-ups affect their health and use of healthcare. It planned to look back at medical records of adults over 40 with COPD. However, the study was withdrawn before enrolling any p…

This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goa…

This study monitors the safety of selumetinib in children aged 3 to 18 with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. Researchers will track potential side effects on the heart, bones, muscles, liver, eyes, and puberty. The goal is to better un…

This study is not testing a new treatment. Instead, it observes how 100 adults with a rare autoimmune disease called NMOSD are managed in everyday Russian clinics. Researchers will collect medical records and follow patients over time to understand their symptoms, treatments, and…

This observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and …

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study watches 137 adults with chronic lymphocytic leukemia (CLL) who are already prescribed acalabrutinib by their doctors. Researchers will track how many patients are still taking the drug after 1 and 2 years. No new treatments or changes are made—just observation of real-…

This study was designed to see if a checklist could help doctors better manage major bleeding in patients taking blood thinners. It planned to include 168 adults in Brazil who were on long-term blood thinners and had a major bleed. The study was withdrawn before any participants …